Louise R. Levine

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

John H. Krystal, Walid Abi‐Saab, Edward Perry et al. · Psychopharmacology · 2004 · 274 citations

Medicine, Neuroscience, Pharmacology +15

The cost of treating anxiety: the medical and demographic correlates that impact total medical costs

Martin Marciniak, Maureen J. Lage, Eduardo Dunayevich et al. · Depression and Anxiety · 2005 · 206 citations

Pharmacy, Pharmacoeconomics, Psychiatry +16

Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

Christian Grillon, Jeremy Cordova, Louise R. Levine et al. · Psychopharmacology · 2003 · 186 citations · Full text

Medicine, Neuroscience, Pharmacology +14

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

Eduardo Dunayevich, J. Erickson, Louise R. Levine et al. · Neuropsychopharmacology · 2007 · 178 citations

Medicine, Pharmacology, Psychiatry +13

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders

Timothy E. Wilens, Lenard A. Adler, Margaret D. Weiss et al. · Drug and Alcohol Dependence · 2008 · 169 citations

Medicine, Pharmacotherapy, Psychiatry +14